Cancer Research
-
Why Broad RAS-Targeting Drugs Mark a Turning Point in Treating Pancreatic Cancer
Discover how the first broad RAS-targeted medicine overcomes decades of failed treatments to offer unprecedented survival benefits for patients.
-
FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653
Reclassification of cancer tissue tests from Class III to Class II aims to lower barriers for diagnostics that match patients to targeted…
-
How Major Medical Centers Partner With Tech Firms for Next-Gen Proton Therapy
Exploring how leading cancer centers like MD Anderson invest in cutting-edge medical technology and strategic partnerships to improve patient outcomes.
-
FDA Approval Moves Astellas’ Padcev Into Curative Bladder Cancer Setting
Volga trial success adds muscle-invasive disease to enfortumab vedotin label, expanding the ADC franchise beyond metastatic use.
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
Exploring how Kazia Therapeutics’ novel nuclear PD-L1 protein degrader, NDL2, works to overcome immunotherapy resistance in advanced solid tumors.
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
Following successful Phase 3 trial results, mRNA platforms are emerging as a versatile, rapid tool for training the immune system to target…
-
Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial
A new study shows that adding an experimental drug to standard chemotherapy significantly improves survival outcomes for patients with metastatic pancreatic cancer.
-
UCSF Scientists Eliminate Deadly Brain Tumors in Mice with B-SYNC Therapy
Engineered B-SYNC CAR-T cells successfully wiped out diffuse midline glioma in mice, paving the way for human clinical trials as early as…
-
Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores
An analysis of how trial designs focused on immune response metrics bypass FDA requirements, potentially delaying approvals for lifesaving cancer combinations.
-
START Opens First Italian Early-Phase Cancer Trial Site in Rome
Strategic partnership establishes first START site in Italy, expanding early-phase cancer trial access to patients in Rome and the Lazio region despite…
-
Researchers find biological clues to why colorectal cancer strikes young adults
A new cell-by-cell tumor atlas sheds light on the aggressive nature of colorectal cancer in younger populations as screening rates expand.
-
UNICORN Trial Finds Deep Responses to Preoperative Immunotherapy
New data from Agenus’ UNICORN trial reveals that short-course neoadjuvant immunotherapy achieves pathologic complete responses in 93% of dMMR colon cancer patients,…
-
Ractigen Launches Phase II Trial for Bladder Cancer Treatment
Ractigen Therapeutics initiates Phase II clinical trial for saRNA therapy RAG-01 to treat non-muscle invasive bladder cancer in China.
-
Blood Cancer UK launches £25m appeal to double leukaemia survival rates
Scientists aim to double leukaemia survival rates using a pioneering multi-treatment clinical trial method that previously transformed prostate cancer care.
-
MIT Nanoparticle Vaccine Tuning Strengthens Immune Responses in Mice
MIT researchers use engineered M13 bacteriophage particles to create more effective cancer vaccines, potentially revolutionizing patient outcomes.
-
KEYNOTE-B49 Shows Pembrolizumab Delays Progression in PD-L1-Positive Breast Cancer
New data from the phase 3 trial indicate that adding immunotherapy to chemotherapy improves progression-free survival in a specific subset of advanced…
-
Flawed Studies Prompt Hormone Therapy Caution for Breast Cancer Survivors
Recent reevaluations of past studies suggest hormone therapy may be safer for breast cancer survivors than previously thought, but doctors remain cautious.
-
Bacteria Pair Cleared Tumours in Mice in 2025 Study; Not Yet Tested in People
Researchers at JAIST found a soil-bacteria pairing destroys human cancer xenografts in mice regardless of immune status, though the team warns this…
-
Could the Moderna-Merck Melanoma Vaccine Win FDA Approval Within Two Years? What We Know
Intismeran met primary endpoints in phase 3, but FDA filing date remains unannounced as companies race toward potential 2027 approval.
-
Epitalon Peptide Shows Mixed Results in Lab Studies on Telomeres and Cancer
While a viral reel claims Epitalon reversed aging, lab data shows it extends telomeres in healthy cells but also activates dangerous pathways…
-
BioSapien Begins First-in-Human MediChip Trial for Rectal Cancer at Burjeel
Abu Dhabi startup BioSapien doses first patient in Phase I trial evaluating its biodegradable MediChip implant to deliver localized chemotherapy directly to…
-
UK Trial Aims to Cut Breast Cancer Radiotherapy from Three Weeks to Five Days
Government-funded FAST-Forward Boost trial recruits 1,000 patients across 39 hospitals to test shorter treatment with targeted boost dose.
-
New Study Shows Tucatinib Delays Progression in Breast Cancer Spread to Brain
A Duke-led trial found adding tucatinib to standard care substantially delayed worsening in HER2-positive breast cancer patients with new brain metastases.
-
GSK to Nearly Double Cancer Drugs in Trials as It Rebuilds Oncology Ahead of HIV Patent Cliff
Amidst looming patent expirations for HIV blockbusters, GSK is aggressively expanding its oncology pipeline, aiming to double late-stage cancer drug studies by…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
New Studies Show Immunotherapy Gaining Ground in Lung, Prostate and Childhood Cancers
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Why Broad RAS-Targeting Drugs Mark a Turning Point in Treating Pancreatic Cancer
-
How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation
-
Boron Neutron Capture Therapy Faces US Coverage Hurdles Over Cost and Data Gaps
-
FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653
-
Biocon’s Pebrilzo FDA Approval Cements Its Role in Affordable Cancer Care
-
Navigating 7% Mortgage Rates: Strategies for Buying a Home Now
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992
























